Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Acute Myeloid Leukemia
  • Ewing's Sarcoma
  • Hodgkin Disease
  • Late Effects
  • Non Hodgkin Lymphoma
  • Non-Metastatic Breast Carcinoma
  • Osteosarcoma
  • Soft Tissue Sarcoma, Adult, Stage IIC
  • Testicular Germ Cell Tumor Mixed
Type
Interventional
Phase
Not Applicable
Design
Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: All patients in the study will benefit from the PASCA post-treatment program with 4 visits : at 1 month (T1), 6 month (T2), 24 month (T3) and 60 month (T4) after the end of treatment.Masking: None (Open Label)Primary Purpose: Prevention

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04671693
Collaborators
  • Malakoff-Humanis
  • Fondation Apicil
  • Fédération Leucémie Espoir
  • Biogaran
  • Le défi Anthony
  • Novartis
  • Roche Pharma AG
Investigators
Principal Investigator: Mauricette MICHALLET, PhD, MD Centre Leon Berard